Abstract

Replacing syrups by tablets as the formulation of antiretroviral drugs in HIV-1-infected Ugandan children made no significant difference to the pharmacokinetics of zidovudine or abacavir (after allowing for the larger dose contained in the tablets), but dose-normalised lamivudine exposure was about 55% higher with tablets than with syrup.